Patent intelligence · US
US 10239912
Modulators of 5′-nucleotidase, ecto and the use thereof
Modulators of 5′-nucleotidase, ecto and the use thereof
Patent details — US 10239912
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 26, 2019
- Expiration
- Mar 21, 2039
- Applicant
- Arcus Biosciences, Inc.
- Claims
- 47
- CPC classes
- A61K, A61K31/70, A61K31/7052, A61K31/706
Quick answer
US 10239912 (Modulators of 5′-nucleotidase, ecto and the use thereof) is held by Arcus Biosciences, Inc.. Status: granted. Granted Mar 26, 2019. Expires Mar 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arcus Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 47
- CPC classes
- A61K, A61K31/70, A61K31/7052, A61K31/706, A61K31/7064, A61K31/7076
More from Arcus Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12415854
Antibodies to TIGIT
granted -
US 12410170
2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
granted -
US 12384773
Thiazole compounds and methods of use thereof
granted -
US 12310965
Treatment of cancer utilizing an identified adenosine fingerprint
granted -
US 12281136
Crystalline forms of a CD73 inhibitor and uses thereof
granted -
US 12226425
Inhibitors of ARG1 and/or ARG2
granted -
US 12195447
Azolopyrimidine for the treatment of cancer-related disorders
granted -
US 12168023
Inhibitors of adenosine 5′-nucleotidase
granted
Related coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy
The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) for the adjuvant treatment of adult patients with muscle-invasive bladder cancer (MIBC) who have ctDNA molecular residual disease (MRD) positivity after radical cystectomy. This approval signifies a major step forward in personalized adjuvant therapy for this patient population.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
FDA Approves Tecentriq for Extensive-Stage Small Cell Lung Cancer
The FDA has granted approval for Tecentriq, a groundbreaking treatment for extensive-stage small cell lung cancer, enhancing options for patients in need.
Frequently asked questions
What is US patent 10239912?
US 10239912 (Modulators of 5′-nucleotidase, ecto and the use thereof) is held by Arcus Biosciences, Inc.. Status: granted. Granted Mar 26, 2019. Expires Mar 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10239912?
Arcus Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 10239912 expire?
Our index shows an expiration date of Mar 21, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.